The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Treatment response monitoring in chronic phase CML (CP-CML) patients receiving tyrosine kinase inhibitor (TKI) therapy in US Oncology network.
Kathryn S. Kolibaba
No relevant relationships to disclose
Hsing-wen Chung
No relevant relationships to disclose
Rahul Dhanda
No relevant relationships to disclose
Debra Rembert
No relevant relationships to disclose
Stephanie Lustgarten
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Jing L. Marantz
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Hui Huang
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD